Benidipine-based Comparison of Angiotensin Receptors, β-blockers, or Thiazide Diuretics in Hypertensive Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

3501 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-05-31

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A number of major clinical trials have demonstrated the clinical benefits of lowering blood pressure and have indicated that a majority of patients with hypertension will require more than one drug to achieve optimal blood pressure control.

There is little data showing which antihypertensive combination best protects patients from cardiovascular events and which best achieves the target blood pressure with the fewest adverse events.

The COPE trial is planned to investigate, in patients with hypertension, which combination of the antihypertensive drugs, angiotensin receptor blockers, β-blockers or thiazide diuretics in addition to a long-acting calcium antagonist, benidipine hydrochloride, is superior to achieve the targeted blood pressure and prevent cardiovascular events with the fewest adverse drug effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension

NCT00971165

Hypertension Cardiovascular Disease

COMPLETED PHASE3

Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension

NCT06783296

Hypertension Renal Denervation Therapy

NOT_YET_RECRUITING NA

Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

NCT00380289

Essential Hypertension

UNKNOWN NA

Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy

NCT00295542

Hypertension

COMPLETED PHASE4

Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs

NCT03560804

Arterial Stiffness Ambulatory Blood Pressure Monitoring

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

angiotensin receptor blockers

benidipine+angiotensin receptor blockers, titlation scheme

Group Type ACTIVE_COMPARATOR

Angiotensin receptor blockers

Intervention Type DRUG

benidipine+angiotensin receptor blocker, titlation scheme

β-blockers

benidipie+β-blockers, titlation scheme

Group Type ACTIVE_COMPARATOR

β-blockers

Intervention Type DRUG

benidipine+β-blockers, titlation scheme

thiazide diuretics

benidipine+thiazide diuretics, titlation scheme

Group Type ACTIVE_COMPARATOR

thiazide diuretics

Intervention Type DRUG

benidipie+thiazide diuretics, titlation scheme

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Angiotensin receptor blockers

benidipine+angiotensin receptor blocker, titlation scheme

Intervention Type DRUG

β-blockers

benidipine+β-blockers, titlation scheme

Intervention Type DRUG

thiazide diuretics

benidipie+thiazide diuretics, titlation scheme

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

benidipine, angiotensin receptor blockers benidipine, β-blockers benidipie, thiazide diuretics

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients who are required a combination therapy with sitting systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg.
* Outpatients aged over 40 years and less than 85 years (inclusive), regardless of sex.
* Previously untreated patients or patients who are on other therapy, which can be converted to 4mg of benidipine.
* Patients who can be treated with benidipine, angiotensin receptor blockers, β-blockers, and thiazide diuretics.

Exclusion Criteria

* Seated systolic blood pressure ≥ 200 mmHg or seated diastolic blood pressure ≥ 120 mmHg.
* Secondary hypertension.
* Type I diabetes mellitus or type 2 diabetes on insulin treatment.
* History of cerebrovascular disorder, myocardial infarction, angina pectoris, coronary angioplasty or coronary artery bypass graft surgery within 6 months prior to enrolment in the study.
* Heart failure (New York Heart Association \[NYHA\] functional classification II, III or IV).
* Chronic atrial fibrillation or atrial flutter.
* Congenital heart disease or a history of rheumatic heart disease.
* Severe peripheral arterial disease (Fontaine Class II, III or IV).
* Serious liver dysfunction (AST or ALT ≥100 IU / l).
* Serious renal dysfunction (serum creatinine ≥ 2mg/dl).
* History of malignancy 5 years prior to study entry.
* Pregnancy.
* Compliance rate \< 70% assessed by a patient interview.
* Known hypersensitivity or contraindication to benidipine, angiotensin receptor blockers, β-blockers, and thiazide diuretics.
* Other serious illness or significant abnormalities that the investigator judges inappropriate for the study

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No